Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

enVVeno Medical (NVNO) Gains from Sales and Divestitures (2020)

enVVeno Medical has reported Gains from Sales and Divestitures over the past 1 years, most recently at $12864.0 for Q4 2020.

For Q4 2020, Gains from Sales and Divestitures changed N/A year-over-year to $12864.0; the TTM value through Dec 2020 reached $12864.0, changed N/A, while the annual FY2020 figure was $12864.0, N/A changed from the prior year.
Gains from Sales and Divestitures for Q4 2020 was $12864.0 at enVVeno Medical.
Over five years, Gains from Sales and Divestitures peaked at $12864.0 in Q4 2020 and troughed at $12864.0 in Q4 2020.